Compare Mesoblast Limited (MESO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs MGM Resorts International — how do they compare? Mesoblast Limited trades at $16.98 (market cap $2.21B), while MGM Resorts International trades at $43.92 (market cap $11.10B). The key difference: MGM Resorts International is far larger — about 5× Mesoblast Limited's market cap, and MGM Resorts International pays a 0.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MGM | |
|---|---|---|
Market Cap | $2.21B | $11.10B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $50.69 |
52-Week Low | $12.88 | $30.72 |
Enterprise Value | $2.21B | $38.40B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MGM Resorts International (MGM) trades at $43.36, down 2.5% with bearish technical signals despite mixed earnings performance. The company reported record Q2 2026 revenue of $17.54B but missed EPS estimates, while analyst consensus remains divided with a $51.14 price target. Recent news highlights ongoing acquisition investigations and BetMGM's expansion in Canadian markets.
MGM faces near-term pressure from earnings volatility and acquisition uncertainty, but maintains strong revenue growth and digital expansion. Key risks include regulatory scrutiny and competitive pressures, while institutional sentiment leans neutral with balanced buy/hold ratings suggesting cautious optimism for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
